AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...
The U.S. Food and Drug Administration in 2019 approved intranasal esketamine to treat depression in adults. However, little data is available on the use of ketamine or esketamine to treat bipolar ...
Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of Maryland ...